Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Certolizumab pegol - UCB

Drug Profile

Certolizumab pegol - UCB

Alternative Names: AutoClicks-Prefilled-Pen; CDP-870; Certolizumab; Cimzia; CIMZIA AutoClicks Prefilled Pen; Cimzia AutoClicks Prefilled Pen; CZP; PHA-738144; Simziya

Latest Information Update: 01 Oct 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator UCB
  • Developer Astellas Pharma; UCB; University of Southampton
  • Class Anti-inflammatories; Antirheumatics; Fab fragments; Monoclonal antibodies; Polyethylene glycols
  • Mechanism of Action Immunosuppressants; Tumour necrosis factor alpha inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Ankylosing spondylitis; Crohn's disease; Plaque psoriasis; Psoriatic arthritis; Rheumatoid arthritis; Spondylitis
  • Registered Non-radiographic axial spondyloarthritis
  • Phase III Interstitial cystitis; Juvenile rheumatoid arthritis
  • Discontinued Cognition disorders

Most Recent Events

  • 15 Oct 2019 UCB Biopharma plans a phase III trial for Plaque psoriasis (In children, In adolescent) in November 2019 (SC) (NCT04123795)
  • 23 Jul 2019 Registered for Rheumatoid arthritis in China (SC)
  • 12 Jun 2019 Updated efficacy data from a phase III RAPID™-axSpA trial trial in Axial spondylitis presented at the 20th Annual Congress of the European League Against Rheumatism (EULAR-2019)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top